TCR-based Therapies for Solid Tumors Summit

Conference themes
The first TCR-based therapy approval in the US and Europe at the start of this year sparked a rush of excitement, investment and collaborations. As further developers move into the clinic and some near commercialization, it's time for this community to unite to address the critical bottlenecks faced in development, from discovery to approval, to guarantee smooth sailing through the clinic.

Scientific Society
Hanson Wade

Notes
Brochure: https://go.evvnt.com/1444012-3?pid=4832

Speakers: Birgit Schultes, Senior Vice President, Cell Therapy, Intellia Therapeutics, Claudia Wagner, Senior Director, Immunology, Head of TCR Discovery and Validation, Immatics, and more

https://go.evvnt.com/1444012-2?pid=4832

Ms. Ellie Saunders